Market Place
Sourcing Support
Alembic Pharma gets tentative nod from USFDA for Ivosidenib tablets
05 Jul 2024 //
ECONOMIC TIMES
FDA Approves Therapy for Blood Cancers Called Myelodysplastic Syndromes
24 Oct 2023 //
PR NEWSWIRE
Servier Announces FDA Approval of TIBSOVO® (ivosidenib tablets) for MDS
24 Oct 2023 //
PR NEWSWIRE
Servier Announces FDA Filing Acceptance and Priority Review for TIBSOVO
15 Aug 2023 //
PR NEWSWIRE
Servier Presents Results for TIBSOVO in IDH1-mutated Myelodysplastic Syndromes
09 Jun 2023 //
PR NEWSWIRE
Les Laboratoires` Tibsovo (ivosidenib) Receives Approval in the Europe
12 May 2023 //
EMA
Servier’s Tibsovo receives marketing approval from EC to treat cancer
11 May 2023 //
PHARMACEUTICAL TECHNOLOGY
Servier receives a positive CHMP opinion for Tibsovo in IDH1-mutated AML and CCA
24 Feb 2023 //
PR NEWSWIRE
Servier Presents Patient Follow Up Data from the Phase 3 AGILE Study at ASH 2022
10 Dec 2022 //
PRNEWSWIRE
Rigel wins US approval of rival drug to Servier leukemia treatment
03 Dec 2022 //
BIOPHARMADIVE
In final pivot from cancer to rare disease, Agios offloads its share of Tibsovo
28 Oct 2022 //
ENDPTS
Mission`s Tapestri Platform to uncover AML resistance mechanisms in TIBSOVO
15 Sep 2022 //
PRNEWSWIRE
TIBSOVO Available from Onco360 for the Treatment of IDH1-mutant AML
15 Sep 2022 //
BUSINESSWIRE
Servier leverages Mission Bio`s Tapestri Platform to uncover AML resistance
15 Sep 2022 //
APNEWS
FDA Confirms Paragraph IV Patent Litigation for Tibsovo (Ivosidenib)
09 Sep 2022 //
FDA
Servier takes aim at US oncology market, doubling R&D lab space in Boston
22 Jul 2022 //
FIERCE BIOTECH
Servier expands Tibsovo label with first combination OK in a rare form of AML
27 May 2022 //
ENDPTS
Servier Announces FDA Approval of TIBSOVO in Combination with Azacitidine
26 May 2022 //
ASIAONE
Phase 3 AGILE Data of TIBSOVO® in Combination with Azacitidine
21 Apr 2022 //
PRNEWSWIRE
Servier submits MAA to EMA for TIBSOVO in IDH1-mutated AML & Cholangiocarcinoma
10 Mar 2022 //
PRNEWSWIRE
Actinium Evaluates Primary Endpoint of Pivotal Phase 3 SIERRA Trial
13 Dec 2021 //
PRNEWSWIRE
New Data at ASH 2021 Reinforces the Strength of Servier`s Hematology Portfolio
04 Nov 2021 //
YAHOOFINANCE
US FDA grants pre-market approval to Thermo Fisher’s Oncomine Dx Target Test
27 Aug 2021 //
PHARMABIZ
Servier Announces FDA Filing Acceptance and Priority Review for TIBSOVO®
05 May 2021 //
BIOSPACE
New Phase III data falls short on OS but supports sNDA for Agios’ Tibsovo
19 Jan 2021 //
THEPHARMALETTER
Ivosidenib Improves Overall Survival in Advanced IDH1+ Cholangiocarcinoma
18 Jan 2021 //
TARGETEDONC
Agios Announces Final Overall Survival Data from Ph3 ClarIDHy Study of TIBSOVO®
18 Jan 2021 //
GLOBENEWSWIRE
CStone Pharma submits NDA for Ivosidenib in Singapore for IDH1-mutated
10 Nov 2020 //
PHARMABIZ
Agios` FDA-approved Tibsovo data doesn`t persuade EU gatekeepers
19 Oct 2020 //
FIERCE PHARMA
European spurn Agios` AML drug Tibsovo, unconvinced by the same thin PhI
16 Oct 2020 //
ENDPTS
Agios Announces Final OS Data from Phase 3 ClarIDHy Study of TIBSOVO®
21 Sep 2020 //
GLOBENEWSWIRE
Agios Announces Publication of TIBSOVO® Phase 3 Data in The Lancet Oncology
19 May 2020 //
GLOBENEWSWIRE
Positive Survival Data from Phase 2 Lung Cancer Trial Accepted for ASCO
14 May 2020 //
HEATBIO
Agios lines up solid PhIII data to back Tibsovo`s use in bile duct cancer
30 Sep 2019 //
ENDPTS
CStone submits new drug application for TIBSOVO
04 Jun 2019 //
BIOSPECTRUM
Cstone partner Agios Announces the Phase 3 ClarIDHy Trial of TIBSOVO ivosidenib
23 May 2019 //
PR NEWSWIRE
FDA approves ivosidenib as first-line treatment for AML with IDH1 mutation
03 May 2019 //
FDA
Agios blood cancer drug lead jumps ship to Aprea Therapeutics
26 Mar 2019 //
FIERCE BIOTECH
Veristat Congratulates Agios Pharmaceuticals on the FDA Approval of TIBSOVO®
17 Aug 2018 //
BUSINESSWIRE
Ivosidenib receives FDA approval to treat AML patients with IDH1 mutation
30 Jul 2018 //
NEWS-MEDICAL
US approves first-in-class targeted AML therapy
24 Jul 2018 //
PHARMA TIMES
TIBSOVO (ivosidenib) Available for Order at Biologics, Inc.
23 Jul 2018 //
BUSINESSWIRE
Agios receives nod for ivosidenib
23 Jul 2018 //
BIOSPECTRUM
Agios scores its second new drug approval, ivosidenib heads to the AML market
21 Jul 2018 //
ENDPTS
